Net 1 UEPS Technologies, Inc. Announces 2010 Third Quarter Results

Osiris Therapeutics Receives FDA Orphan Drug Designation For Stem Cell Treatment For Type 1 Diabetes
Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must …

Read more on PharmaceuticalOnline

Net 1 UEPS Technologies, Inc. Announces 2010 Third Quarter Results
Net 1 UEPS Technologies, Inc. today announced results for the three and nine months ended March 31, 2010. Revenue during 3Q 2010 was $72.3 million, a year over year increase of 29% in US dollars and a decline of 2% in constant currency.

Read more on PR Newswire via Yahoo! Finance